FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to pathophysiology and pharmacology, and can be used to treat patients with pathological conditions, where the dysfunction the endothelium is observed. Method comprises administering of dalargin in the form of a sterile crystalloid solution for infusion.
EFFECT: use of the invention makes it possible to treat endothelial dysfunction by preventing the cleavage of tight contact proteins, reducing the number and area of intercellular spaces of endothelial cells, and reducing their apoptosis by dalargin.
6 cl, 8 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PREVENTING INTERCELLULAR CONTACTS OF ENDOTHELIOCYTES IN DYSFUNCTION OF ENDOTHELIUM | 2020 |
|
RU2741766C1 |
| METHOD OF PREVENTING ENDOTHELIAL DAMAGE IN CRITICALLY ILL PATIENTS | 2023 |
|
RU2812594C1 |
| METHOD OF TREATING ENDOTHELIAL DYSFUNCTION IN DIABETES MELLITUS | 2019 |
|
RU2703567C1 |
| PEPTIDE THAT IMPROVES THE FUNCTIONAL PROPERTIES OF THE VASCULAR ENDOTHELIUM, A PHARMACEUTICAL COMPOSITION BASED ON IT AND THE METHOD FOR ITS APPLICATION | 2021 |
|
RU2769051C1 |
| METHOD FOR EVALUATING LYMPHOCYTE EFFECT ON DEVELOPING ENDOTHELIAL DYSFUNCTION | 2011 |
|
RU2482487C2 |
| MONOCLONAL ANTIBODIES AGAINST ACTIVATED PROTEIN C | 2008 |
|
RU2539729C2 |
| MEDICATION, METHOD OF OBTAINING MEDICATION, AND METHOD OF TREATMENT FOR CORNEA EDEMA AND OTHER EARLY BULLOUS KERATOPATHY MANIFESTATIONS | 2008 |
|
RU2357743C1 |
| METHOD OF ESTIMATING ANGIOGENIC POTENTIAL OF PROGENOTOR CELLS IN PATIENTS WITH CARDIOVASCULAR DISEASES | 2011 |
|
RU2548801C2 |
| METHOD OF DIAGNOSTICS OF ORGANISM SYSTEM INFLAMMATORY RESPONSE FOR CRITICAL STATES | 2007 |
|
RU2328219C1 |
| WAY OF CORRECTION OF ENDOTHELIAL DYSFUNCTION | 2007 |
|
RU2359686C2 |
